Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

55.83 +0.04 (+0.07%)
Official Closing Price Updated: 7:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,105,523
Open 55.43
Bid (Size) 55.81 (1)
Ask (Size) 56.16 (1)
Prev. Close 55.79
Today's Range 54.85 - 56.05
52wk Range 39.35 - 61.10
Shares Outstanding 2,222,113,553
Dividend Yield 4.30%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma. 
Via Benzinga
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management. 
Via Stocktwits

Performance

YTD
-1.69%
-1.69%
1 Month
-2.21%
-2.21%
3 Month
-5.16%
-5.16%
6 Month
+16.05%
+16.05%
1 Year
+8.77%
+8.77%

More News

Read More
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Via Talk Markets
Topics Stocks / Equities
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
Via Benzinga
Topics Government
Exposures Political
Nuclear Power Is Solving the World’s Looming Energy Crisis
Via InvestorPlace
Topics Government World Trade
Exposures Political Tariff
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
My “Two-Step” Plan for Surviving Shaky Markets – and Coming Out Ahead
Via InvestorPlace
Topics Government World Trade
Exposures Political Tariff
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
From Bristol Myers Squibb
Via Business Wire
How to Read Trump’s Tariff Playbook – and Prepare for His Next Moves
Via InvestorPlace
Topics Government World Trade
Exposures Political Tariff
Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow
Via StockStory
Organon (OGN) Q4 Earnings Report Preview: What To Look For
Via StockStory
Gapping S&P500 stocks in Monday's session
Via Chartmill
What's Going On With Bristol Myers Squibb Stock On Monday?
Via Benzinga
Exposures Product Safety
Royalty Pharma Earnings: What To Look For From RPRX
Via StockStory
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
From Bristol Myers Squibb
Via Business Wire
MarketBeat Week in Review – 02/03 - 02/07
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Exposures Artificial Intelligence Interest Rates Tariff
Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
Via MarketBeat
US Stocks Likely To Open On A Mixed Note: Amazon, Pinterest, Take-Two Among Stocks To Watch
Via Benzinga
S&P 500 Gains For 3rd Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.